Navigation Links
Can Obama Plan Tackle Diabetes Crisis? Epinex Test Could Help

IRVINE, Calif., March 10 /PRNewswire/ -- Diabetes will be a huge burden on President Obama's $634 billion plan to expand and improve healthcare coverage. Epinex Diagnostics, a private biomedical company located in Irvine, California, has developed a new diabetes monitoring device that could relieve the burden of diabetes on our healthcare system.


The Epinex G1A(TM) Rapid Diabetes Monitoring Index Test is a revolutionary monthly rapid test that uses glycated albumin to measure how much damage has been done to the body by excess sugar. The Epinex G1A(TM) test will be a significant asset to help keep costs down by introducing a monthly testing paradigm that has been proven effective. This test could allow doctors to take action sooner than current diabetes testing methods, reducing the severity and cost of diabetes and its complications, which include blindness, kidney failure and cardiac disease.

President Obama recently acknowledged, "crushing health care costs...drag down our economy, bankrupt our families, and represent the fastest-growing part of our budget." In an unprecedented commitment to a new, more effective approach to healthcare, the President has taken the challenge to keep raging costs under control by proposing the "largest investment ever" in preventive care.

Diabetes eats up an enormous chunk of our current healthcare resources. It has become the greatest healthcare crisis of our time, affecting one in three Americans. Last year alone, direct medical costs for diabetes totaled $116 billion, a 32% increase since 2002. Despite current efforts to manage the epidemic, the toll of diabetes continues to spiral out of control. However, pouring more resources into ineffective programs will only waste money.

Continuing to address the diabetes epidemic using methods of the past threatens to set up our health care system for failure. "The current treatment paradigm for diabetes doesn't work," explains Epinex CEO, Asad Zaidi. "With our current financial crisis, Epinex is working on a product that will help save our already over-burdened healthcare system billions of dollars, while helping diabetics manage their disease more effectively."

About Epinex Diagnostics, Inc.

Epinex Diagnostics is a privately owned medical device company with a vision to help alleviate the current healthcare crisis through the development of innovative point-of-care technologies using rapid diagnostic tests. Please find further information about the company and the G1A(TM) test at

SOURCE Epinex Diagnostics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cord Blood America Sees Significant Positives in President Obamas Lifting of Stem Cell Funding Restrictions
2. Environmental Tectonics Corporations BioMedical Divisions Hyperbaric Chambers Address U.S. President Obamas Initiative to Computerize Medical Records
3. Obama Advisor Joins Connecticut and International Scientists at New Haven Stem Cell Symposium
4. Growing Interest in DNA-Based Genetic Testing Among African American with Historic Election of President Elect Barack Obama
5. Cord Blood America Salutes President-Elect Obamas Promise to Lift Restrictions on Stem Cell Research
6. McCain and Obama on Bio-threat Detection and Pandemic Response: QualSec Weighs in
7. Old and new therapies combine to tackle atherosclerosis
8. World Hepatitis Alliance Calls on Governments to Take Urgent Action to Tackle Chronic Viral Hepatitis B & C Epidemic
9. New Report Tackles the Changing Landscape for Alzheimers Diagnostics and Treatments
10. Atherotech Announces Addition of ApoAI Heart Disease, Diabetes Risk Marker to VAP(R) Test
11. Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes
Post Your Comments:
(Date:11/26/2015)... November 26, 2015 --> ... specializing in imaging technologies, announced today that it has received ... of the Horizon 2020 European Union Framework Programme for Research ... clinical trial in breast cancer. , --> ... --> --> The study aims ...
(Date:11/25/2015)... and HOLLISTON, Mass. , Nov. ... (Nasdaq: HART ), a biotechnology company developing bioengineered ... Jim McGorry will present at the LD ... 2015 at 2:30 p.m. PT. The presentation will be ... 30 days. Management will also be available at the ...
(Date:11/25/2015)... Oregon , November 25, 2015 ... Market Research Report is a professional and in-depth ... industry.      (Logo: ) ... overview of the industry including definitions, classifications, applications ... is provided for the international markets including development ...
(Date:11/24/2015)... Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... New York on Wednesday, December 2 at ... , president and CEO, will provide a corporate overview. ... at 1:00 p.m. ET/10:00 a.m. PT . ... will provide a corporate overview. --> th Annual ...
Breaking Biology Technology:
(Date:11/16/2015)... 16, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced expansion of its TDDI product portfolio ... controller and display driver integration (TDDI) solutions designed ... new TDDI products add to the previously-announced ... (WQHD resolution), and TD4322 (FHD resolution) solutions. All ...
(Date:11/10/2015)... LONDON , Nov. 10, 2015 /PRNewswire/ ... segmented on the basis of product, type, ... segments included in this report are consumables, ... this report are safety biomarkers, efficacy biomarkers, ... in this report are diagnostics development, drug ...
(Date:11/2/2015)... Nov. 2, 2015  SRI International has been awarded ... preclinical development services to the National Cancer Institute (NCI) ... provide scientific expertise, modern testing and support facilities, and ... pharmacology and toxicology studies to evaluate potential cancer prevention ... The PREVENT Cancer Drug Development Program is an NCI-supported ...
Breaking Biology News(10 mins):